RaQualia Pharma Inc. (4579.T)
JPY 340.0
(1.8%)
JPY 340.0
(1.8%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -323.66 Million JPY | -144.74% |
| 2022 | 723.39 Million JPY | -4.29% |
| 2021 | 755.78 Million JPY | 224.52% |
| 2020 | -606.98 Million JPY | -11460.38% |
| 2019 | 5.34 Million JPY | 100.48% |
| 2018 | -1.1 Billion JPY | -1800.4% |
| 2017 | -58.12 Million JPY | 92.02% |
| 2016 | -728.11 Million JPY | 60.73% |
| 2015 | -1.85 Billion JPY | -190.23% |
| 2014 | -638.92 Million JPY | 42.35% |
| 2013 | -1.1 Billion JPY | 61.86% |
| 2012 | -2.9 Billion JPY | -51.62% |
| 2011 | -1.91 Billion JPY | -46.54% |
| 2010 | -1.3 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -78.1 Million JPY | 62.09% |
| 2024 Q2 | -245.75 Million JPY | -214.64% |
| 2023 Q4 | -206.02 Million JPY | -43.95% |
| 2023 FY | -323.66 Million JPY | -144.74% |
| 2023 Q1 | -148.37 Million JPY | -157.91% |
| 2023 Q2 | 173.85 Million JPY | 217.17% |
| 2023 Q3 | -143.11 Million JPY | -182.32% |
| 2022 Q1 | -120.9 Million JPY | -120.62% |
| 2022 FY | 723.39 Million JPY | -4.29% |
| 2022 Q4 | 256.21 Million JPY | 11120.13% |
| 2022 Q3 | -2.32 Million JPY | -100.39% |
| 2022 Q2 | 590.4 Million JPY | 588.33% |
| 2021 Q1 | 188.57 Million JPY | 105.72% |
| 2021 Q2 | 114.25 Million JPY | -39.41% |
| 2021 Q4 | 586.45 Million JPY | 539.31% |
| 2021 Q3 | -133.49 Million JPY | -216.84% |
| 2021 FY | 755.78 Million JPY | 224.52% |
| 2020 Q3 | -239.19 Million JPY | -82.13% |
| 2020 FY | -606.98 Million JPY | -11460.38% |
| 2020 Q2 | -131.33 Million JPY | 59.97% |
| 2020 Q1 | -328.12 Million JPY | -161.08% |
| 2020 Q4 | 91.66 Million JPY | 138.32% |
| 2019 FY | 5.34 Million JPY | 100.48% |
| 2019 Q3 | -221.78 Million JPY | -7.08% |
| 2019 Q4 | 537.17 Million JPY | 342.21% |
| 2019 Q1 | -102.93 Million JPY | 60.42% |
| 2019 Q2 | -207.11 Million JPY | -101.22% |
| 2018 FY | -1.1 Billion JPY | -1800.4% |
| 2018 Q4 | -260.06 Million JPY | -4.98% |
| 2018 Q1 | -311.64 Million JPY | -176.86% |
| 2018 Q2 | -285.1 Million JPY | 8.52% |
| 2018 Q3 | -247.74 Million JPY | 13.1% |
| 2017 Q1 | -65.53 Million JPY | 63.46% |
| 2017 FY | -58.12 Million JPY | 92.02% |
| 2017 Q4 | 405.45 Million JPY | 329.8% |
| 2017 Q3 | -176.43 Million JPY | 20.38% |
| 2017 Q2 | -221.6 Million JPY | -238.16% |
| 2016 Q2 | -330.52 Million JPY | -472.31% |
| 2016 FY | -728.11 Million JPY | 60.73% |
| 2016 Q1 | 88.77 Million JPY | 124.59% |
| 2016 Q3 | -307.01 Million JPY | 7.11% |
| 2016 Q4 | -179.34 Million JPY | 41.58% |
| 2015 Q3 | -571.02 Million JPY | -12.08% |
| 2015 FY | -1.85 Billion JPY | -190.23% |
| 2015 Q1 | -412.72 Million JPY | 37.72% |
| 2015 Q2 | -509.5 Million JPY | -23.45% |
| 2015 Q4 | -361.09 Million JPY | 36.76% |
| 2014 FY | -638.92 Million JPY | 42.35% |
| 2014 Q4 | -662.7 Million JPY | -51.26% |
| 2014 Q3 | -438.13 Million JPY | 15.87% |
| 2014 Q2 | -520.76 Million JPY | -152.99% |
| 2014 Q1 | 982.68 Million JPY | 211.54% |
| 2013 Q1 | -558.82 Million JPY | 12.38% |
| 2013 Q4 | 315.42 Million JPY | 160.63% |
| 2013 Q3 | -520.24 Million JPY | -50.96% |
| 2013 Q2 | -344.62 Million JPY | 38.33% |
| 2013 FY | -1.1 Billion JPY | 61.86% |
| 2012 Q3 | -662.82 Million JPY | 30.34% |
| 2012 Q1 | -653.42 Million JPY | -7.46% |
| 2012 FY | -2.9 Billion JPY | -51.62% |
| 2012 Q4 | -637.75 Million JPY | 3.78% |
| 2012 Q2 | -951.45 Million JPY | -45.61% |
| 2011 Q3 | -768.36 Million JPY | -38.78% |
| 2011 FY | -1.91 Billion JPY | -46.54% |
| 2011 Q4 | -608.05 Million JPY | 20.86% |
| 2011 Q1 | 13.78 Million JPY | 0.0% |
| 2011 Q2 | -553.63 Million JPY | -4116.22% |
| 2010 FY | -1.3 Billion JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 184.287% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | 38.574% |
| GNI Group Ltd. | 8.09 Billion JPY | 103.999% |
| Linical Co., Ltd. | 338.26 Million JPY | 195.683% |
| Trans Genic Inc. | 4.08 Million JPY | 8023.182% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 77.491% |
| Soiken Holdings Inc. | -662.2 Million JPY | 51.123% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | 334.275% |
| AnGes, Inc. | -7.43 Billion JPY | 95.648% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 74.874% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 95.5% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | 273.365% |
| NanoCarrier Co., Ltd. | -780 Million JPY | 58.505% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | 71.926% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 73.229% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | 60.16% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 73.471% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 77.24% |
| PeptiDream Inc. | 3.03 Billion JPY | 110.661% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 83.304% |
| Ribomic Inc. | -1.02 Billion JPY | 68.4% |
| SanBio Company Limited | -2.64 Billion JPY | 87.759% |
| Healios K.K. | -3.82 Billion JPY | 91.534% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 72.291% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 78.272% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 77.357% |
| StemRIM | -2.02 Billion JPY | 83.993% |
| CellSource Co., Ltd. | 923.14 Million JPY | 135.061% |
| FunPep Company Limited | -933.41 Million JPY | 65.325% |
| Kringle Pharma, Inc. | -854.15 Million JPY | 62.107% |
| Stella Pharma Corporation | -763.74 Million JPY | 57.622% |
| TMS Co., Ltd. | -960.04 Million JPY | 66.287% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | 71.358% |
| Cuorips Inc. | -632.18 Million JPY | 48.802% |
| K Pharma,Inc. | 260.33 Million JPY | 224.328% |
| Takara Bio Inc. | 1.48 Billion JPY | 121.869% |
| ReproCELL Incorporated | -31.41 Million JPY | -930.279% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | 1327.015% |
| StemCell Institute Inc. | 310.98 Million JPY | 204.078% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | 326.07% |
| CellSeed Inc. | -846.53 Million JPY | 61.766% |